Whether dangerous staphylococci survive in the nose depends on what other bacteria are present – and how they obtain iron.
FDA won’t take action against GLP-1 compounders as it rethinks tirzepatide shortage
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
October 19, 2024